Efficacy and safety of thalidomide with hydroxyurea in sickle cell anemia: a quasi-experimental clinical trial
Combining thalidomide with HU significantly reduced VOCs and transfusion requirements, improved Hb and HbF%, and decreased HbS levels.
Authors
- Ajit Kumar Bishoyi (ORCID: https://orcid.org/0000-0002-7739-5616)
- Venkatarao Epari (ORCID: https://orcid.org/0000-0002-1841-352X)
- Priyanka Samal (ORCID: https://orcid.org/0000-0002-9129-7967)
- Anindita Paul
- Harshwardhan Bahirat
Institutions
- Institute of Medical Sciences and Sum Hospital (IN)
Publication Details
- Journal
- Blood Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1007/s44313-025-00068-4
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00